Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
Gieffers C, Kluge M, Merz C, Sykora J, Thiemann M, Schaal R, Fischer C, Branschädel M, Abhari BA, Hohenberger P, Fulda S, Fricke H, Hill O. Gieffers C, et al. Among authors: hohenberger p. Mol Cancer Ther. 2013 Dec;12(12):2735-47. doi: 10.1158/1535-7163.MCT-13-0323. Epub 2013 Oct 7. Mol Cancer Ther. 2013. PMID: 24101228
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy.
Mühlenberg T, Ketzer J, Heinrich MC, Grunewald S, Marino-Enriquez A, Trautmann M, Hartmann W, Wardelmann E, Treckmann J, Worm K, Bertram S, Herold T, Schildhaus HU, Glimm H, Stenzinger A, Brors B, Horak P, Hohenberger P, Fröhling S, Fletcher JA, Bauer S. Mühlenberg T, et al. Among authors: hohenberger p. Mol Cancer Ther. 2019 Nov;18(11):1985-1996. doi: 10.1158/1535-7163.MCT-18-1224. Epub 2019 Jul 15. Mol Cancer Ther. 2019. PMID: 31308077
Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus.
Bohle W, Schlag P, Liebrich W, Hohenberger P, Manasterski M, Möller P, Schirrmacher V. Bohle W, et al. Among authors: hohenberger p. Cancer. 1990 Oct 1;66(7):1517-23. doi: 10.1002/1097-0142(19901001)66:7<1517::aid-cncr2820660714>3.0.co;2-i. Cancer. 1990. PMID: 2208003
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors.
Lübbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, Matthias M, Dörken B, Herrmann F, Gürtler R, Hohenberger P, Haas N, Sohr R, Sander B, Lemke AJ, Ohlendorf D, Huhnt W, Huhn D. Lübbe AS, et al. Among authors: hohenberger p. Cancer Res. 1996 Oct 15;56(20):4686-93. Cancer Res. 1996. PMID: 8840985 Clinical Trial.
386 results